These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29755783)

  • 1. Erratum to updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases.
    Kennedy A; Cohn M; Coldwell DM; Drooz A; Ehrenwald E; Kaiser A; Nutting CW; Rose SC; Wang EA; Savin MA
    J Gastrointest Oncol; 2018 Apr; 9(2):E13-E14. PubMed ID: 29755783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases.
    Kennedy A; Cohn M; Coldwell DM; Drooz A; Ehrenwald E; Kaiser A; Nutting CW; Rose SC; Wang EA; Savin MA
    J Gastrointest Oncol; 2017 Aug; 8(4):614-624. PubMed ID: 28890810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
    Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
    J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust evidence for long-term survival with
    Jakobs TF; Paprottka KJ; Raeßler F; Strobl F; Lehner S; Ilhan H; Trumm CG; Fendler WP; Sommer W; Paprottka PM
    Eur Radiol; 2017 Jan; 27(1):113-119. PubMed ID: 27059858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres.
    Kennedy AS; Ball D; Cohen SJ; Cohn M; Coldwell DM; Drooz A; Ehrenwald E; Kanani S; Rose SC; Nutting CW; Moeslein FM; Savin MA; Schirm S; Putnam SG; Sharma NK; Wang EA
    J Gastrointest Oncol; 2015 Apr; 6(2):134-42. PubMed ID: 25830033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients.
    Saxena A; Meteling B; Kapoor J; Golani S; Morris DL; Bester L
    Ann Surg Oncol; 2015 Mar; 22(3):794-802. PubMed ID: 25323474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-Based Integration of Yttrium-90 Radioembolization in the Contemporary Management of Hepatic Metastases from Colorectal Cancer.
    Wang DS; Louie JD; Sze DY
    Tech Vasc Interv Radiol; 2019 Jun; 22(2):74-80. PubMed ID: 31079714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review.
    Feretis M; Solodkyy A
    World J Gastrointest Oncol; 2020 Feb; 12(2):228-236. PubMed ID: 32104553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.
    Fendler WP; Lechner H; Todica A; Paprottka KJ; Paprottka PM; Jakobs TF; Michl M; Bartenstein P; Lehner S; Haug AR
    J Nucl Med; 2016 Apr; 57(4):517-23. PubMed ID: 26742710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
    Saxena A; Kapoor J; Meteling B; Morris DL; Bester L
    Ann Surg Oncol; 2014 Apr; 21(4):1296-303. PubMed ID: 24337647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review.
    Rosenbaum CE; Verkooijen HM; Lam MG; Smits ML; Koopman M; van Seeters T; Vermoolen MA; van den Bosch MA
    J Nucl Med; 2013 Nov; 54(11):1890-5. PubMed ID: 24071510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers.
    Coldwell D; Sangro B; Salem R; Wasan H; Kennedy A
    Am J Clin Oncol; 2012 Apr; 35(2):167-77. PubMed ID: 21127414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases.
    Jia Z; Paz-Fumagalli R; Frey GT; Sella DM; McKinney JM; Wang W
    Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):899-905. PubMed ID: 31104533
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
    Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
    J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer.
    Kennedy AS; Ball DS; Cohen SJ; Cohn M; Coldwell D; Drooz A; Ehrenwald E; Kanani S; Rose SC; Nutting CW; Moeslein FM; Savin MA; Schirm S; Putnam SG; Sharma NK; Wang EA;
    Clin Colorectal Cancer; 2016 Jun; 15(2):141-151.e6. PubMed ID: 26541321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
    Kousik V; Promila P; Verma R; Gupta A
    Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing Synchronous Liver Metastases in Colorectal Cancer.
    Cetin B; Bilgetekin I; Cengiz M; Ozet A
    Indian J Surg Oncol; 2018 Dec; 9(4):461-471. PubMed ID: 30538373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.